Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Stockholders' Equity (Tables)

Note 7 - Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

		*March 31,*				*December 31,*
		*2024*				*2023*
Stock price		$	11.10			$	12.00
Risk-free interest rate			4.21	%			3.84	%
Expected dividend yield			—				—
Expected term in years			3.5				3.8
Expected volatility			162	%			148	%

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

		*Number of*				*Weighted*
		*Units and*				*Average Grant*
		*Awards*				*Date Fair Value*
		(in thousands)
Unvested balance at December 31, 2023			1,311			$	196.21
Granted			—				—
Forfeited			—				—
Vested			(283	)			85.50
Unvested balance at March 31, 2024			1,028			$	226.69

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

										*Weighted*
										*Average*
		*Number*				*Weighted*				*Remaining*				*Aggregate*
		*of Options*				*Average*				*Contractual*				*Intrinsic Value*
		*(in thousands)*				*Exercise Price*				*Term (years)*				*(in thousands)*
Outstanding at December 31, 2023			22,474			$	85.50				9.5			$	—
Granted			—			$	—							$	—
Exercised			—			$	—							$	—
Cancelled/forfeited			—			$	—							$	—
Expired			—			$	—							$	—
Outstanding at Balance at March 31, 2024			22,474			$	85.50				9.2			$	—
Expected to vest			16,304			$	85.50				9.2			$	—
Exercisable			6,170			$	85.50				9.2			$	—

Share-Based Payment Arrangement, Cost by Plan [Table Text Block]

		*For the three months ended*
		*March 31,*				*March 31,*
		*2024*				*2023*
Research and development		$	45			$	—
General and administrative			146				11
Total stock-based compensation expense		$	191			$	11

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

						*Weighted*
						*Average*				*Aggregate*
						*Exercise*				*Intrinsic Value*
		*Warrants*				*Price*				*(in thousands)*
Outstanding, December 31, 2023			524,601			$	32.42			$	—
Granted			441,076				22.55
Exercised			(220,538	)			22.55
Outstanding, March 31, 2024			745,139			$	29.50			$	—

Warrant [Member]

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

		January 2023				New Series A				New Series B
		Warrants				Warrants				Warrants
Stock price		$	14.25			$	14.25			$	14.25
Risk-free interest rate			4.40	%			4.02	%			4.40	%
Expected dividend yield			—				—				—
Expected term in years			2.1				5.0				1.5
Expected volatility			185	%			138	%			187	%